Course Report: 3rd Middle East Camp for Parkinson's, Movement Disorders and Neuromodulation

3rd Middle East Camp for Parkinson’s Disease, Movement Disorders and Neuromodulation
World Trade Centre, Dubai, UAE
October 5-6, 2017

 

The 3rd Middle East Camp for Parkinson’s Disease, Movement Disorders and Neuromodulation was held in Dubai, UAE, October 5-6, 2017. Course Description

The fields of Parkinson’s disease and Movement Disorders are under served in the Middle Eastern region, which spans numerous countries and includes a population of over 500 million inhabitants. The understanding of Parkinson’s disease and Movement Disorders is rapidly evolving and numerous therapeutic medical and surgical treatment options are available on the market.

The 3rd Middle East camp for Parkinson’s, Movement Disorders and Neuromodulation was the follow-up to the popular 1st and 2nd Middle East Camps. The course provided up to date discussions on Parkinson’s disease and other movement disorders and all available advance therapies in the field. The course focused on unmet needs in detail based on past course evaluations. The camp also included an Allied Health track to the curriculum. 

Target Audience

Course participants pose for a photo during the 3rd Middle East Camp for Parkinson’s Disease, Movement Disorders and Neuromodulation.This course was recommended for Movement disorder neurologists: General Neurologists, Geriatricians, Neurosurgeons, Allied health professionals and Neurologists in-training.

The course was attended by 74 delegates, 46 from the medical track and 28 from the allied health track, from the following countries: Australia, Bahrain, Bangladesh, Canada, France, India, Iran, Jordan, Kuwait, Morocco, Pakistan, Saudi Arabia, Spain, Sudan, Sweden, United Arab Emirates, and Uzbekistan.

Course Learning Objectives
  • Recognize the clinical presentation, management and progression of PD.
  • Understand the rational of rehabilitative approaches in people with PD.
  • Describe the key areas of rehabilitation in people with PD.
  • Define a full subjective and objective assessment for a person with PD, using appropriate recommended measurement tools.
  • Describe the rational for designing and modifying a patient- specific treatment plan.
  • Identify strategies for collaborating with physicians and other health professionals

 

Participant Feedback

Upon conclusion of the course, participants indicated that they would change the following in the practice:

  • Change in management of Tardive dyskinesia
  • Diagnosis, serenity grading, trying newer management options
  • Improve my diagnostic skills on movement disorders
     

The major strengths of this course were:

  • Communication regarding recent development in PD
  • Comprehensive review
  • Meeting experts, exchanging experiences
  • OT and PT subjects
     
Course Directors and Faculty

Medical Track Course Directors

Jawad A. Bajwa, MD
Riyadh, Saudi Arabia

Zakiyah Aldaajani, MD
Riyadh, Saudi Arabia

Allied Health Track Course Directors

Jawad A. Bajwa, MD
Riyadh, Saudi Arabia

Hanan Khalil, PhD
Irbid, Jordan

Course Faculty (17)

Medical Track

Mishal Abu Al-Melh, BSc, BM, BCh, MD, FRCPC
Kuwait City, Kuwait

Amaal AlDakheel, MD
Riyadh, Saudi Arabia

Manal Badawi, FRCPC
Jeddah, Saudi Arabia

Mohit Bhatt MD, DM
Mumbai, India

Stanley Fahn, MD
New York, NY, USA

Christopher Goetz, MD
Chicago, IL, USA

Henry Houlden
London, United Kingdom

Beomseok (BJ) Jeon, MD, PhD
Seoul, Korea

Katie Kompoliti, MD
Chicago, IL, USA

Mie Rizig
London, United Kingdom

Pournamy Sarathchandran, MD, DM
Dubai, United Arab Emirates

Samer Tabbal, MD
Beirut, Lebanon


Allied Health Track

Firas Alfwaress, CCC-SLP, PhD
Irbid, Jordan

Natalie Allen, PhD
Sydney, Australia

Mariella Graziano, BSc (Hons)
Esch-sur-Alzette, Luxembourg

Bhanu Ramaswamy, OBE, FCSP, DProf
Sheffield, United Kingdom

Vonita Singh, PhD
Dubai, United Arab Emirates
 

Top

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice